James D Colandene

Title: Innovations by James D. Colandene: A Spotlight on Therapeutic Advancements

Introduction

James D. Colandene, located in North Potomac, Maryland, is an esteemed inventor known for his contributions to the field of therapeutic compositions. With a focus on innovations in fibrinolytic treatment, he has secured one patent that showcases his dedication to advancing medical therapies.

Latest Patents

Colandene's notable patent is titled "Reversibly inactivated acidified plasmin composition." This invention provides a fibrinolytic composition that serves as a therapeutic option for patients experiencing thrombotic occlusion. The composition includes a reversibly inactivated acidified serine protease that is substantially free of a plasminogen activator, paired with a low buffering capacity buffer, and optionally, a stabilizing agent. This inventive approach aims to enhance the efficacy of treatments concerning blood clots and improve patient outcomes.

Career Highlights

James Colandene currently works at Grifols Therapeutics Inc., where he continues to innovate and contribute to the field of therapeutics. His work is instrumental in developing advanced medical solutions that address critical health issues related to thrombotic events.

Collaborations

Colandene collaborates with several professionals in his field, notably working alongside Thomas P. Zimmerman and Valery Novokhatny. Their combined expertise fosters a collaborative environment that promotes innovation and the development of new therapeutic approaches.

Conclusion

James D. Colandene's contributions to medical science through his patent underscore the importance of innovative solutions in healthcare. His work not only represents a significant advancement in the treatment of thrombotic occlusions but also highlights the role of dedicated inventors in driving medical innovation forward. Through collaboration and a commitment to excellence, Colandene continues to make impactful strides in the therapeutic landscape.